Article
Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?
American journal of clinical pathology - 3 Jul 2018
Fang Hong, Kapoor Prashant, Gonsalves Wilson I, Frederick Lori A, Viswanatha David, Howard Matthew T, He Rong, Morice William G, McPhail Ellen D, Greipp Patricia T, Ansell Stephen M, Kyle Robert A, Gertz Morie A, Paludo Jonas, Abeykoon Jithma, King Rebecca L
Abstract excerpt
OBJECTIVES: Lymphoplasmacytic lymphoma (LPL) remains a poorly defined entity, even with the discovery of MYD88L265P mutations and association with Waldenström macroglobulinemia (WM). Among bone marrow (BM)-based, low-grade B-cell lymphoma with plasmacytic differentiation (LGBLPD) and immunoglobulin M (IgM) paraproteins, we sought to determine whether MYD88L265P defines a distinct entity and can help refine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.